throbber
JOURNAL OF OCULAR PHARMACOLOGY
`AND THERAPEUTICS
`Volume 12. Number 4, 1996
`Mary Ann Liebert, Inc.
`
`The In Vitro and In Vivo Ocular
`
`Pharmacology of Olopatadine
`(AL-4943A), an Effective
`Anti—Allergic/Antihistaminic Agent
`
`.l.M. YANNI, DJ. STEPHENS, S.T. MILLER, LK. WEIMER,
`G. GRAFF, D. PARNELL, LS. LANG, .l.M. SPELLMAN,
`M.T. BRADY, and DA. GAMACl-IE
`
`Allergy/Inflammation Research, AICOII Laboratories, Inc. Fort Worth, Texas
`
`ABSTRACT
`
`[(z)—l1-[3—(dimethylamino)propylidene]—6,ll-dihydro-
`Olopatadine (AL—4943A; KW-4679)
`dibenzlb,e]oxepine-2 acetic acid hydrochloride] is an anti-allergic agent which inhibits mast cell
`mediator release and possesses histamine H. receptor antagonist activity. Studies were conducted to
`characterize the in vitra and in vivo pharmacological profile of this drug relevant to its topical ocular
`use. AL-4943A inhibits histamine release in a concentration-dependent fashion (ICso = 559 pM) from
`human conjunctival mast cell preparations in vitro. Histamine release was not stimulated by
`AL4943A at concentrations as high as 10 mM.
`In contrast, ketotifen stimulated histamine release
`at concentrations slightly higher than effective inhibitory concentrations. AL-4943A did not display
`any in vitro cyclooxygenase or 5-lipoxygenase inhibition. Topical ocular application of AL-4943A
`effectively inhibits antigen- and histamine-stimulated conjunctivitis
`in guinea pigs. Passive
`anaphylaxis in guinea pig conjunctiva was attenuated by AL4943A applied 30 min prior to
`intravenous or
`topical ocular antigen challenge (ED,0 values 0.0067% and 0.0170%, w/v,
`respectively). Antihistaminic activity in viva was demonstrated using a model of histamine-induced
`vascular permeability in guinea pig conjunctiva. AL—4943A applied topically from 5 min to 24 hrs
`prior
`to histamine challenge effectively and concentration-dependent]y inhibited the vascular
`permeability response, indicating the compound has an acceptable onset and a long duration of action.
`Drug concentrations 5—fold greater than those effective against histamine-stimulated conjunctival
`responses failed to inhibit vascular permeability responses induced with either serotonin or
`Platelet-Activating-Factor.
`These data indicate that
`the anti-histaminic effect observed with
`AL-4943A is specific. These anti-allergic/antihistaminic activities of AL-4943A observed in
`preclinical model systems have been confirmed in clinical trials in allergic patients.
`
`INTRODUCTION
`
`[(z)-11-[3-(dimethylamino) propylidene]—6,l l-dihydro-
`Olopatadine (AL4943A; KW-4679)
`dibenz-[b,e]oxepine-2 acetic acid hydrochloride] is an anti-allergic/antihistarninic agent synthesized
`(I) and under development by Kyowa Hakko Kogyo Co., Ltd, for the treatment of bronchial asthma,
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1004, Page 1
`
`389
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 1
`
`

`

`allergic rhinitis and chronic urticaria. AL-4943A's anti-allergic efficacy following systemic
`administration has been demonstrated in rat and guinea pig models of immediate hypersensitivity
`(1,2,3).
`Inhibition of passive anaphylaxis persisted for 9 hrs following oral administration of
`AL-4943A (3) indicating a prolonged duration of action.
`In vitro receptor binding studies have
`demonstrated the affinity of AL-4943A for the Hl-histamine receptor (1,4,5). Additionally, these
`studies have shown selectivity of AL—4943A for the H1 receptor and demonstrated a lack of
`significant interaction with alpha adrenergic, muscarinic, doparninergic and numerous other receptors
`(5).
`
`Because of the reported long duration of anti-allergic activity, coupled with selective
`anti-histaminic activity, studies were undertaken to evaluate the utility of this compound for use in
`allergic conjunctivitis. AL-4943A's effects on human conjunctival mast cell mediator release, on
`cyclooxygenase and 5-lipoxygenase enzymes, and in models of allergen- and histamine-stimulated
`conjunctivitis following topical ocular administration were characterized. The results of those
`investigations are reported below.
`
`METHODS AND MATERIALS
`
`Inhibition of Histamine Release from RBL Rat Basophils
`
`RBL-2H3 is a rat basophilic leukemia cell line which secretes both histamine and serotonin
`upon degranulation. RBLs were passively sensitized overnight with lgE specific for dinitrophenol
`(DNP) tagged to bovine serum albumin according to Benacerraf and Levine (6). Cells were washed
`with PIPES buffer, and incubated for 15 min at 37°C with AL-4943A prior to challenge with antigen
`(DNP, 10 ng/ml). Supematants were analyzed for histamine content using a commercially available
`radioimmunoassay (RIA) system (AMAC, 1nc., Westbrook, ME).
`
`Histamine Release from Human Conjunctival Mast Cells
`
`Human conjunctival tissue was obtained from organ/tissue donors. Upper and lower palpebral
`conjunctivas were aseptically collected within 8 hrs of death (average time 4.5 hrs) and transported
`in Dexsol® corneal preservation medium (Chiron Ophthalmics, Irvine, CA). Conjunctival tissue was
`weighed and placed into a glass 20 m1 screw—cap bottle containing culture medium (RPMI 1640)
`supplemented with heat inactivated fetal bovine serum (20%), L-glutamine (2 mM), penicillin (100
`units/ml), streptomycin (100 mg/ml), amphotericin B (2.5 mg/ml), and HEPES (10 mM). Tissues and
`medium were transferred to sterile petri dishes for overnight equilibration at 37°C prior to enzymatic
`digestion.
`Modification of a previously reported method for obtaining monodispersed cell suspensions
`containing mast cells (7) was employed using human conjunctival tissue. Briefly, tissues were
`transferred to Tyrode’s buffer (in mM: 137 NaCl, 2.7 KCl, 0.35 NaHzPOM 1.8 CaClz, 0.98 MgClz,
`11.9 NaI-ICO3, 5.5 glucose) containing 0.1% gelatin (TGCM) for enzymatic treatment. Tissues were
`incubated with 200 U each of collagenase (Type IV) and hyaluronidase (Type 1-3) per gram of tissue
`for 30 min at 37° C. Following enzyme digestion, tissues were washed with an equal volume of
`TGCM over Nitex® filter cloth (Tetko, Briarcliff Manor, NY). Two digestions, completed as
`described above, were followed by additional digestion steps using 2000 U each of collagenase and
`hyaluronidase per gram of tissue for 30 min at 37°C.
`The filtrate obtained from each digestion was centrifuged (825 g, 7 min), and pelleted cells were
`resuspended in calcium/magnesium free Tyrode’s buffer (TG). Pooled cells from all digestions were
`centrifuged (825 g, 30 min) over a 1.058 g/L Percoll® cushion. Mast cell enriched cell pellets were
`resuspended and washed in TO buffer. Viability and number of mast cells were determined by vital
`dye (trypan blue) exclusion and toluidine blue 0 staining of the harvested cell suspensions. Cell
`suspensions containing 5000 mast cells were added to TGCM containing tubes. The cells were
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1004, Page 2
`
`390
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 2
`
`

`

`treated with test compound 15 min prior to challenge with anti-human IgE (10 pg/ml). The final
`volume per reaction tube was 1.0 ml. The release reaction was terminated by the addition of ice-cold
`TGCM and centrifugation (500 g, 7 min). Supematants were collected and stored at -20°C until
`histamine analysis (described above).
`
`Inhibition of Cyclooxygenase In vitro
`
`Inhibition of cyclooxygenase activity from sheep vesicular glands by AL-4943A was assayed
`as follows: Lipid-depleted sheep vesicular gland microsomal powder (10 mg) was homogenized in
`ice-cold 50 mM phosphate buffer (pH 7.4) supplemented with 1% Tween-20, 2 pM hematin, and 5
`mM diethyldithiocarbamic acid. The solubilized microsomal preparation (10 pg) was added to the
`incubation chamber containing 3.0 ml 50 mM phosphate buffer (pH 7.4), 0.5 mM phenol, and 0.5 pM
`hematin and pre-equilibrated to 30° C. AL-4943A, dissolved in dimethyl sulfoxide (DMSO), was
`added to the incubation chamber. The mixture was stirred for 2 min before initiating the reaction by
`the addition of 30 pl of a freshly prepared aqueous solution of 10 mM ammonium arachidonate.
`Indomethacin, also in DMSO (5 30 pl), served as reference compound. Cyclooxygenase activity was
`determined polarographically by monitoring the rate of oxygen consumption, due to the conversion
`of arachidonic acid to prostaglandin Hz (8).
`
`Inhibition of 5-HETE and LTB, Formation In virra
`
`The potency of AL4943A to suppress 5-hydroxy eicosatetraenoic acid (5-HETE) and
`leukotriene l3,1 (LTB4) formation was investigated in calcium ionophore Mama—stimulated neutrophils
`isolated from rabbit peripheral blood. Neutrophils from peripheral blood were isolated by standard
`procedures. Briefly, heparinized/calcium chelated blood was obtained from five New Zealand Albino
`rabbits by heart puncture. Red cells were removed at 4°C by dextran sedimentation (9). White cells,
`contained in the supernatant fraction, were sedimented by centrifugation and contaminating red cells
`removed by hypotonic lysis. The white cell pellet obtained following hypotonic red cell lysis and
`centrifugation was resuspended in Dulbecco's phosphate buffered saline (Caz’lMg2'—free). The cell
`suspension was layered onto a 60% Histopaque-1083/40% Histopaque-l 1 l9 cushion. The neutrophil
`pellet at the bottom of the tube following centrifugation was washed and resuspended in 1/25 the
`original blood volume. Aliquots of the cell suspension were pretreated for 5 min at 37°C with either
`carrier (DMSO) or test article dissolved in DMSO.
`Immediately thereafter, CaCl2 was added to the
`cell suspension and cells stimulated by the addition of 5 pl of a mixture containing ll—“CJ-
`arachidonic acid and calcium ionophore (Anm) in DMSO. The final concentrations of CaClz,
`[l-"C]-arachidonic acid and calcium ionophore were 5.0 mM, 52 pM and 5.0 pM, respectively.
`After 3 min of incubation at 37° C, reactions were terminated by the addition of 2 volumes of acetone.
`Extraction and reversed phase (Cm-5 p) HPLC analysis of [l-“Cl-labelled arachidonic acid metabo-
`lites were conducted as previously described by Graff and Anderson (10).
`
`Passive Anaphylaxis in Conjunctiva
`
`Guinea pigs or rats (5-8/group) were passively sensitized with anti-ovalbumin serum injected
`subconjunctivally in one eye. Twenty-four (24) hrs after passive sensitization. ovalbumin (0A) was
`administered either intravenously (i.v.) or topically onto the eye.
`The anti-allergic effect of AL—4943A following i.v. antigen administration was determined as
`follows: Thirty (30) min prior to i.v. antigen challenge, the animals received 20 pl of AL-4943A or
`saline applied topically to the eye. The animals were then challenged i.v. via the marginal ear vein
`or lateral tail vein with 1.0 ml of an 0A2Evans Blue solution (100 pgzl mg, guinea pigs;
`I mg:2.5
`mg, rats). Responses were quantitated as previously described by Yanni et a]. (l l).
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1004, Page 3
`
`391
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 3
`
`

`

`For assessment of the allergic response following topical ocular antigen challenge, 20 pl of
`ovalbumin (1.0%, w/v) was administered to the sensitized eye 5 min after topical ocular application
`of AL-4943A or saline (20 p1). During dose response studies, the order of compound administration
`was randomized. Thirty (30) min later, the reaction was quantitated, using the following scoring
`scheme (maximum score per animal = 10):
`
`Congestion (refers to palpebral and bulbar conjunctiva)
`0- Normal
`
`1 - Pink conjunctiva
`2 - Red conjunctiva
`3 — Dark red conjunctiva; petechiae present
`
`Swelling
`0- None
`
`I — Any swelling on lower lid only
`2 - Swelling upper and lower lid, lids partially closed
`3 - Lids everted, very swollen, lids at least half closed
`4- Swelling of both lids and side of face
`
`Discharge
`0- None
`
`1 - Glazed, glassy appearance
`2 - Moist lids and surrounding hair
`3 - Moist lids and surrounding hair, thicker mucous-like
`
`Histamine-induced Vascular Permeability in Guinea Pig Conjunctiva
`
`Male Dunkin Hartley Viral Antibody Free outbred guinea pigs (Charles River Labs, Portage,
`Ml), 250-350 grams, (6/group) were injected iv. via the marginal ear vein with 1.0 ml of Evans Blue
`dye (1.0 mg/ml). Forty-five (45) min post dye injection, 20 pl of test compound or saline vehicle
`was applied topically onto one eye of each experimental animal. Thirty min following topical drug
`application, the guinea pigs were anesthetized and challenged subconjunctivally with histamine (300
`ng/ 10 pl). Responses were quantitated as previously described (1 1).
`All modifications of the pretreatment interval between compound administration and histamine
`challenge are noted in the Results section.
`
`Platelet Activatin
`
`
`Conjunctiva
`
`
`
`Factor PAF- or Serotonin
`
`
`5-HT -induced Vascular Penneabilit
`
`
`
`Male Sprague Dawley rats (Harlan Sprague Dawley, Houston, TX), 125—200 grams, (6/group)
`were injected i.v. via the lateral tail vein with 1.0 ml Evans Blue dye (2.5 mg/ml). Approximately
`20 min post dye injection, 20 pl of test compound or vehicle was applied topically onto one eye of
`the experimental animal. Thirty (30) min later, each animal was anesthetized and challenged
`subconjunctivally with PAP (30 ng/lO pl) or 5-HT (100 ng/lO pl) in the treated eye. Thirty (30)
`min after challenge, the animals were killed, and responses were quantitated as noted for histamine.
`
`Communds
`
`levocabastine (Janssen
`Japan);
`AL-4943A (Kyowa Hakko Kogyo Co., Ltd., Tokyo,
`Pharmaceutica, Beerse, Belgium); histamine dihydrochloride, ovalbumin, 5-hydroxytryptamine
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1004, Page 4
`
`392
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 4
`
`

`

`hydrochloride, Percoll®, goat lgG, ketotifen fumarate, b0vine serum albumin, dinitrofluorobenzene,
`cyproheptadine hydrochloride (Sigma Chemical Co., St. Louis, MO); Evans Blue dye (Aldrich
`Chemical Co., Milwaukee, WI); PAF (Biomol, Plymouth Meeting, PA); anti-human lgE (goat-derived
`IgG) (Cortex Biochem, San Leandro, CA).
`Immediately prior to in vivo use, all compounds were prepared as solutions or suspensions in
`saline (0.9% NaC] in water) at the concentrations noted in the Results section. All solutions and
`suspensions were prepared on a weight/volume basis to reflect the percentage of free acid or base for
`all in vivo experiments.
`
`Statistical Analyses
`
`Dunnett’s t-test (12) was used to compare the mean of each treatment group with the mean of
`the vehicle control group. Linear regression was used to analyze dose response and calculate
`effective doses (EDm).
`
`RESULTS
`
`The anti-allergic activity of AL—4943A, defined as inhibitory activity on basophil and mast cell
`degranulation, was assessed in vitro. The addition of AL-4943A 15 min before antigen challenge to
`cultured RBL cells inhibited histamine release in a concentration dependent manner. The 1C,o value
`was calculated to be 803 pM. When human conjunctiva] mast cells were treated with AL-4943A for
`15 min prior to anti-lgE challenge, histamine release was also significantly reduced in a concentration
`dependent fashion. The 1C5.) value obtained in human conjunctiva] mast cells was 559 1 277 uM.
`Dose response curves obtained using both cell types are presented in Figs. 1A and 18. The reference
`drug, ketotifen, examined in the human conjunctiva] mast cell also significantly inhibited histamine
`release. However, at concentrations 3 times greater than the maximally effective concentration,
`ketotifen caused a significant release of histamine from these cells (Fig. 18). Additional in vitro
`evaluations of AL-4943A for cyclooxygenase or 5-]ipoxygenase activity failed to detect significant
`activity (data not presented).
`Anti-allergic activity noted in vitro was confirmed in vivo using two models of passive
`conjunctiva] anaphylaxis. Significant inhibition of i.v. antigen-stimulated allergic conjunctivitis was
`observed in both rats and guinea pigs when AL-4943A was applied topically onto the eye prior to
`antigen challenge. Significant concentration dependent inhibition was noted in both species (Table
`l). AL—4943A was more efficacious when evaluated in guinea pigs compared to rats (80% inhibition
`vs. 40% inhibition, respectively, at 0.1%).
`The anti-allergic activity observed following i.v. antigen challenge was further evaluated using
`topical ocular antigen challenge of passively sensitized guinea pigs. The application of AL-4943A
`onto the eye of sensitized animals 30 min, 4 hrs or 8 hrs before allergen instillation significantly
`attenuated the allergic response (Table 2). The EDso values detemiined in these experiments were
`0.017%, 0.053% and 0.100%, respectively.
`When evaluated for topical ocular antihistaminic activity in viva, AL-4943A potently inhibited
`histamine-induced vascular permeability in the conjunctiva. The compound was applied topically 5,
`15 or 30 min, 2, 4, 8 or 24 hrs prior to histamine injection. Concentration dependent inhibition was
`observed (Table 3). The ED” values derived from these data are 0.019%, 0.004%, 0.002%, 0.0014%,
`0.0056%. 0.035% and 0.114%, respectively.
`The ability of AL—4943A to affect the response of the contralateral eye to histamine challenge
`following topical ocular administration was also assessed. AL-4943A or levocabastine (0.05%) was
`applied to one eye and histamine was subsequently injected subconjunctivally in the contralateral eye.
`The dmgs’ effects were quantified as described above. AL—4943A (0.1%) applied 30 min before
`histamine challenge failed to decrease the response in the contralateral eye (197 1 40, vehicle vs. 199
`_+_ 39, AL-4943A treated) while inhibiting the response in the treated eye by 95%. In contrast,
`
`393
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1004, Page 5
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 5
`
`

`

`levocabastine did significantly reduce the response in the untreated eye (28%). These results indicate
`a lack of systemic effect following topical administration of AL—4943A.
`The specificity of AL-4943A noted in histamine and antigen stimulated in vivo models was
`evaluated using conjunctival vascular permeability models induced by 5-HT and PAF. AL-4943A
`applied at a concentration (0.01%) and pretreatment interval (30 min) before challenge proven to
`prevent histamine-induced responses greater than 70 % failed to significantly inhibit the response in
`the conjunctiva to either 5-HT or PAF (Table 4).
`
`[A] RBL Cells
`
`100
`
`so
`
`AL-4943A
`
`. .
`
`\ .
`
`
`
`~55
`
`-5.0
`
`4.5
`
`-4.0
`
`' p<0.05. Dunnett's Hut.
`-3.5
`-3.0
`.25
`
`Dose log(M)
`
`[B] Human Conjunctival Tissue Mast Cells
`
`%Inhibition
`
`%inhibition
`
`100
`
`80
`
`60
`
`ketotifen
`
`/
`
`'/
`
`
`
`
`'
`
`a
`
`_ AL-4943A
`
`’\
`
`2/-
`
`\ i
`
`' p<0.05, Dunnett's t-test.
`
`-3.5
`
`-3.0
`
`-25
`
`-2.0
`
`i
`i F
` -5.5
`
`-5.0
`
`4,5
`
`4.0
`
`Inhibition of Histamine Release from RBL Cells (A) and Human
`FIGURE 1. AL—4943A’s
`Conjunctival Tissue Mast Cells (B).
`
`Dose log(M)
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1004, Page 6
`
`394
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 6
`
`

`

`TABLE 1
`
`Effect of AL-4943A on Passive Anaphylaxis in Rat or Guinea Pig Conjunctiva
`Following Intravenous Antigen Challenge'M
`
`Species
`
`Compound
`
`Conc.
`(96, w/v)
`
`Permeability
`Score
`(x 1 SD.)
`
`
`96 Change
`
`Regression
`Analysis
`
`Rat
`
`NaCl
`
`AL-4943A
`
`Guinea
`1
`p g
`
`NaCl
`AL-4943A
`
`0.9
`
`1.0
`0.1
`0.01
`
`0.9
`0.1
`0.01
`0.001
`
`308 1 48
`
`147 1 30 *
`185 1 37 *
`266 149
`
`506 1 124
`102 i 76 *
`264 1 161 *
`334 1133
`
`--
`
`-52
`-40
`-1 4
`
`-80
`~48
`-34
`
`y = -53x + 144
`slope t = p < 0.0001
`r - 0.821
`
`y = -11(>x - 0.48
`slope t = p < 0.0054
`r = 0.975
`
`* p < 0.05. Dunnett‘s t test
`a Interval between compound administration and antigen challenge: rat 20 min; guinea pig 30 min.
`
`TABLE 2
`
`Effect of AL—4943A on Passive Anaphylaxis in Guinea Pig Conjunctiva
`Following Topical Ocular Antigen Challenge
`
`
`Compound Pre-
`treatment
`Interval
`
`
`Conc.
`(96, w/v)
`
`Score
`(x1 S.D.)
`
`96
`Change
`
`EDso
`(96, w/v)
`
`Regression
`Analysis
`
`NaCl
`
`30 min
`
`AL—4943A
`
`NaCl
`
`4 hr
`
`AL-4943A
`
`NaCl
`
`8 hr
`
`AL-4943A
`
`0.9
`
`1.0
`0.1
`0.01
`0.001
`
`0.9
`
`1.0
`0.1
`0.01
`0.001
`
`0.9
`
`1.0
`0.1
`0.01
`0.001
`
`8.2 1 1.3
`
`3.8 1 0.8 *
`3.2 1 1.3 '
`4.5 1 1.1 "
`5.3 1 2.0 *
`
`7.2 1 1.0
`
`2.3 1 1.5 *
`3311.5”
`4.2 1 2.0 *
`5.3 11.2
`
`7.2 1 1.7
`
`1.7 10.8 *
`4.2 1 0.8 *
`5.4 11.1 *
`5.8 1 0.8
`
`--
`
`-53
`-61
`-45
`-3S
`
`--
`
`-67
`-53
`-42
`-2()
`
`--
`
`-77
`-41
`-25
`-19
`
`0.0170
`
`y - -l.08x + 2.17
`t slope = p < 0.020
`r =- 0.542
`
`0.0529
`
`y = —0.98x + 2.32
`tslope-p<0.0018
`r - 0.602
`
`0.100
`
`y - -l.37.\' + 2.17
`t slope = p < 0.0001
`r - 0.856
`
`* p < 0.05. Dunnett's t test
`——————\
`
`395
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1004, Page 7
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 7
`
`

`

`TABLE 3
`
`The Effect of AL—4943A on Histamine-induced Vascular Permeability in Guinea Pigs
`
`Compound
`
`Conc.
`(96, w/v)
`
`Permeability
`Pre-
`Score
`treatment
`Interval
`(x1 S.D.)
`
`
`96
`Change
`
`EDso
`(96)
`
`Regression
`Analysis
`
`NaCl
`
`5 min
`
`AL-4943A
`
`0.9
`
`0.3
`0.03
`0.003
`
`324 1 S9
`
`94 1 65 *
`165 1 74 *
`197 1 56 *
`
`NaCl
`
`15 min
`
`0.9
`
`431 1 91
`
`AL-4943A
`
`0.1
`0.03
`0.01
`0.001
`0.0001
`0.00001
`
`NaCl
`
`30 min
`
`0.9
`
`AL-4943A
`
`AL-4943A
`
`2 hr
`
`NaCl
`
`4 hr
`
`AL-4943A
`
`NaCl
`
`8 hr
`
`AL-4943A
`
`NaCl
`
`24 hr
`
`AL-4943A
`
`0.1
`0.01
`0.001
`0.0001
`
`0.1
`0.01
`0.001
`0.0001
`
`0.9
`
`1.0
`0.1
`0.01
`0.001
`
`0.9
`
`1.0
`0.1
`0.01
`0.001
`
`0.9
`
`1.0
`0.1
`0.01
`
`98 1 87 *
`180 1 40 *
`238 1 49 *
`240 1 43 *
`302 1 SS *
`370 1 73
`
`228 1 25
`
`15 1 15 *
`69 1 33 *
`125 1 36 *
`195 1 S3
`
`17 1 3 *
`146 1 87 *
`201 1 105 *
`342 1 66
`
`423 1 47
`
`S 1 8 "
`66176"
`263 1 49 *
`240 1 69 *
`
`374 1 4S
`
`10 1 8 "
`152 1 33 *
`247 1 29 *
`389 1 S9
`
`347 1 27
`
`12 118 *
`2311 35 *
`302 1 69
`
`--
`
`-71
`-49
`-39
`
`--
`
`-77
`-58
`-45
`-44
`~30
`-14
`
`--
`
`-94
`~70
`~45
`-15
`
`-96
`-66
`-52
`-19
`
`~-
`
`-99
`-84
`~38
`-43
`
`--
`
`-97
`-60
`-34
`4
`
`-—
`
`-96
`-33
`-l 3
`
`0.019
`
`0.004
`
`y :- -52x + 73
`slope t = p < 0.013
`r = 0.571
`
`y = -59x + 73
`slope t = p < 0.0001
`r = 0.814
`
`0.002
`
`y = -61x - 56
`slope t - p < 0.0001
`r = 0.888
`
`0.0014
`
`y = -103x - 82
`slope t = p < 0.0001
`r = 0.850
`
`0.0056
`
`y = -90x + 8
`slopetx p<0.0001
`r = 0.826
`
`0.035
`
`y = -123x + 14
`slope t = p < 0.0001
`r - 0.969
`
`0.114
`
`y - -l45x + 36
`slope t = p < 0.0001
`r = 0.909
`
`* p < 0.05, Dunnett's t test
`
`
`|PR2018-01020 and |PR2018-01021, Exhibit 1004, Page 8
`
`396
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 8
`
`

`

`TABLE 4
`
`The Effect of AL—4943A on Serotonin- and
`
`Platelet Activating Factor-induced Vascular Permeability
`
`Stimulus
`
`Compound
`
`Cone.
`(96, w/v)
`
`Permeability
`Score
`(x i S.D.)
`
`96 Change
`
`Serotonin
`
`NaCl
`
`AL—4943A
`
`cyproheptidine
`
`PAF
`
`NaCl
`
`AL-4943A
`
`* p < 0.05, Dunneu’s t test
`
`0.9
`
`0.01
`
`0.01
`
`0.9
`
`0.01
`
`385 i 59
`
`304 i 57
`
`118 1 52 "
`
`409 i 74
`
`404 i 49
`
`--
`
`-21
`
`-69
`
`--
`
`-1
`
`DISCUSSION
`
`The mast cell has long been considered to play a primary role in the pathogenesis of immediate
`hypersensitivity reactions. One therapeutic approach used in ocular allergic disease involves the use
`of mast cell stabilizers (13). Human conjunctiva] tissue is estimated to contain as many as 10,000
`mast cells per mm3 (14). Drugs developed as mast cell stabilizers for the treatment of asthma have
`been available for topical use in allergic conjunctivitis. Recently,
`the concept of mast cell
`heterogeneity has been illustrated and accepted (15,16). Mast cells from different species and from
`different tissues within the same animal differ with respect to their morphological, cytochemica], and
`functional properties.
`Importantly,
`the mast cell populations also differ in their responses to
`pharmacological agents (14,17). These findings suggest that efficacious anti-allergic drugs for treating
`conjunctivitis should have demonstrated efficacy on the target cell, the human conjunctiva] mast cell.
`Data presented clearly demonstrate AL-4943A’s concentration dependent inhibition of human
`conjunctiva] mast cell histamine release. Greater than 90% inhibition was achieved without observable
`histamine release due to cytotoxicity. AL-4943A, at concentrations 10 times greater than the
`maximally effective concentration, inhibited histamine release by greater than 90%. These data are
`in contrast to those obtained with ketotifen. Although ketotifen is more potent than AL-4943A at
`inhibiting mast cell mediator release, it causes pro-inflarmnatory mediator release at concentrations
`only 3 times greater than the maximally effective concentration. These data indicate that AL-4943A
`affords a larger safety margin than does ketotifen.
`The relevance of AL-4943A's effect on mast cells based upon the potency (IC,o= 559 pM)
`becomes apparent when the molar concentration is converted to percentage weight/volume (559 uM
`- 209 [Lg/ml - 0.0209952, w/v). Because the conjunctiva is the target tissue for this compound,
`penetration and transport into the eye do not confound drug delivery. For these reasons, and because
`of the efficacy observed following topical ocular administration, the potency on human conjunctiva]
`mast cells appears acceptable.
`Anti-allergic activity observed in vitro was confirmed in viva using models of passive
`anaphylaxis. Concentration dependent inhibition was noted following topical ocular administration
`of AL-4943A prior to antigen challenge. Significant activity was noted 8 hrs after administration of
`AL-4943A. The rat did not appear to be as responsive as the guinea pig to drug treatment. This can
`be partially explained by the two species' relative reactivity to the major vasoactive amines released
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1004, Page 9
`
`397
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 9
`
`

`

`from activated mast cells (rat/serotonin; guinea pig/histamine) (18,19,20) and the activity of
`AL—4943A on histamine Hl receptors (1,4,5).
`The reported in vitro histamine H1 receptor antagonism was observed in vivo as well.
`AL—4943A applied topically onto the eye from 5 min to 24 hrs before histamine challenge
`significantly attenuated the vascular permeability response. A comparison of EDso values obtained
`in our laboratory at time intervals from 15 min to 4 hrs after dosing indicate that AL-4943A is
`equipotent to levocabastine (15 min EDsos: 0.004%, AL—4943A vs. 0.0072%, levocabastine; 4 hr:
`0.0056%, AL-4943A vs. 0.0080%, levocabastine). These results are consistent with the similar
`affinities of the two compounds observed in radioligand binding studies (5). Assessment of activity
`at 24 hrs following compound administration demonstrates AL—4943A’s long duration of action.
`These in viva results are supported by the data obtained in ex vivo experiments in which AL-4943A
`occupied 80% of lung histamine H. receptors within an hour of oral dosing, and approximately 50%
`of the receptors were still occupied 24 hrs later (4).
`AL-4943A’s ability to inhibit vascular permeability responses in the conjunctiva is agonist
`specific. No significant reductions in vascular permeability responses induced with serotonin or PAF
`were observed with concentrations of AL-4943A which inhibit histamine stimulated responses by
`70%. The specificity and selectivity of AL—4943A has been further characterized utilizing in vitra
`radioligand binding methodology (5). Data obtained from those studies confirm a lack of interaction
`at adrenergic, doparninergic and muscarinic receptors. This suggests that AL—4943A’s side-effect
`potential may be minimal.
`In addition, when AL-4943A was applied to one eye in a concentration
`which inhibited the response of that eye by 95%, no effect could be observed in the contralateral eye.
`This indicates that the potential for developing side effects is further reduced by the lack of systemic
`effect noted following topical ocular administration. AL-4943A's lack of side effects has been
`confirmed in clinical trials.
`
`Pharmacological intervention in allergic conjunctivitis has been primarily through the use of
`histamine Hl antagonists in combination with a-adrenergic agonists (22). Recently, Berdy et al. (23)
`demonstrated that Hl antagonists effectively relieve pruritis, conjunctival injection, and erythema in
`human volunteers. The other primary approach in managing ocular allergic diseases has been the use
`of mast cell stabilizers (24).
`The data presented demonstrate that AL-4943A combines both of these activities in one
`selective, topically effective, anti~allergiclantihistaminic agent. The compound possesses a rapid onset
`and long duration of action in preclinical models of allergic ocular disease. The anti-allergic and
`human conjunctival mast cell stabilizing activity of AL~4943A, coupled with its selective
`antihistaminic activity, suggests that the compound has potential utility when used prophylactically
`and therapeutically. This affords distinct advantages over other agents currently used for the
`treatment of ocular allergic diseases. Clinical trials with a topical ocular formulation of AL-4943A
`have been completed, and a New Drug Application (NDA) has been filed.
`
`REFERENCES
`
`l.
`
`2.
`
`3.
`
`4.
`
`Ohshima, E., Otaki, S., Sato, H., Kumazawa, T., Obase, H., Ishii, A., Ishii, H., Ohmori, K.,
`and Hirayama, N. Synthesis and antiallergic activity of ll-(aminoalkylidene)—6,l l-dihydrodi-
`bensz,e]oxepin derivatives. J. Med. Chem, 35:2074-2084, 1992.
`
`Inhibitory effect of KW-4679 on allergic models in
`Ishii, H., Kitamura, S., and Ohmori, K.
`rats. Jpn. J. Pharmacol, 55 (Suppl 1):375P, 1991.
`
`Ishii, H., Manabe, H., Sasaki, Y., Satoh, H., Tamura, T., and Ohmori, K. Pharmacological
`properties of a new antiallergic agent KW-4679. Jpn. J. Pharmacol., 46 (Suppl 1):284P, 1988.
`
`Nonaka, H., Ishii, A., and Kase, H. Effect of KW-4679, a novel antiallergic agent, on
`histamine Hl receptor. Jpn. J. Pharmacol., 61 (Suppl l):87P, 1993.
`
`|PR2018—01020 and |PR2018-01021, Exhibit 1004, Page 10
`
`398
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 10
`
`

`

`Sharif, N.A., Xu, s.x., and Yanni, J.M. Olopatadine (AL-4943A): Ligand binding and
`functional studies on a novel, long acting H.-selective histamine antagonist/anti—allergic agent
`for use in allergic conjunctivitis. J. Ocular Phannacol. Then, in press.
`
`Immunological specificity of delayed and immediate
`Benacerraf, B. and Levine, B.B.
`hypersensitivity reactions. J. Exp. Med, 115:1023-1035, 1962.
`
`Undem, BJ., Brendel, J.B., Hinh, ’1‘., Buckner, C.K., and Graziano, F.M. Comparative studies
`of mediator release from guinea pig lung mast cells and basophils. Am. Rev. Resp. 0119.,
`133:763-768, 1986.
`
`Instrumental improvements for rapid, detailed
`Cook, l-l.W., Ford, 0., and Lands, W.E.M.
`kinetic studies of oxygenase activity. Anal. Biochem., 96:341-387, 1979.
`
`Skoog, WA. and Beck, W.S. Studies on the fibrinogen, dextran, and phytohemagglutinin
`methods of isolating leukocytes. Blood, 11:436-454, 1956.
`
`l-[4-[3-[4[bis(4-fluorophenyl) hydroxymethyl] -1-piperidinyl]-
`Graff G. and Anderson, L.A.
`propoxy]
`-3-methoxyphenyl] ethanone (AHR-5333): a selective human blood neutrophil
`S-lipoxygenase inhibitor. Prosraglandins, 38:473-496, 1989.
`
`Yanni, J.M., Weimer, L.K., Glaser, R.K., Lang, L.S., Robertson, S.M., and Spellman, J.M.
`Effect of lodoxamide in in vitro and in viva conjunctiva] immediate hypersensitivity responses
`in rats. Int. Arch. Allergy Immunol, 101:102-106, 1993.
`
`Dunnett, C.W. A multiple comparison procedure for comparing treatments with a control.
`Am. Stat. Assoc, 50:1096-1121, 1955.
`
`.1.
`
`Abelson, M. and Schaefer, K. Conjunctivitis of allergic origin: Immunologic mechanisms and
`current approaches to therapy. Surv. Ophthalmol, 38 (Suppl)2115-132,1993.
`
`Irani, A., Butrus, S., Tabbara, K., and Schwartz, L. Human conjunctiva] mast cells: Distribu-
`tion of MCr and MCrC in vernal conjunctivitis and giant papillary conjunctivitis. J. Allergy
`Clin Immunol, 86:34-39, 1990.
`
`Katz, H., Stevens, R., and Austen, K. Heterogeneity of mammalian mast cells differentiated
`in vivo and in vitro. J. Allergy Clin. lmmunol., 762250-259, 1985.
`
`Irani, A., and Schwartz, L. Mast cell heterogeneity. Clin. Exp. Allergy, 192143-155, 1989.
`
`Befus, A.D., Dyck, N., Goodacre, R., and Bienenstock, J. Mast cells from the human intestinal
`lamina propria: isolation, histochemica] subtypes and functional characterization. J. Immunol,
`13822604-2610, 1987.
`
`Rowley, D. and Benditt, E. S-Hydroxytryptamine and histamine as mediators of the vascular
`injury produced by agents which damage mast cells in rats. J. Exp. Med, 103:399-411, 1956.
`
`Inflammation
`Maling, H.M., Webster, M.E., Williams, M.A., Saul, W., and Anderson, W. Jr.
`induced by histamine, serotonin, bradykinin and compound 48/80 in the rat: Antagonists and
`mechanisms of action. J. Pharmacol. Exp. Ther., 191:300-310, 1974.
`
`Rithche, D., Sierchio, 1., Capetola, R., and Rosenthale, M. SRSA-mediated bronchospasm by
`pharmacologic modification of lung anaphylaxis in vivo. Agenm Actions, ll:396-401,198l.
`
`399
`
`|PR2018—0102O and |PR2018-01021, Exhibit 1004, Page 11
`
`10.
`
`ll.
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`l7.
`
`l8.
`
`19.
`
`20.
`
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1004, Page 11
`
`

`

`21.
`
`22.
`
`23.
`
`24.
`
`Yanni, J.M., Stephens, DJ., Parnell, D.W., and S

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket